Publication: Pharmacovigilance Outsourcing | Deloitte US | Life Sciences has been added to your bookmarks.
Emerging PV business models
Resulting from regulatory changes, new pharmacovigilance (PV) operating models should focus on four key components to become proactive, resource-efficient, and business-aligned. This paper provides an overview of the outsourcing market and examines these key components to efficiently manage and improve PV delivery models.
Many pharmaceutical companies are turning to alternative delivery models to increase efficiency and capacity. These range from internal redesign to full-scale outsourcing, with many variations in between. Although elements of pharmacovigilance have been outsourced for a number of years, its efficiency and effectiveness has not been ideal and is only now maturing to the point where it can be considered more seriously.
Pharmaceutical companies should focus four key components of a PV operating models to become proactive, resource -efficient, and business-aligned:
- Core Capabilities
- Global Networks